AMGN

Amgen Inc demonstrates distinctive profitability metrics within the biotechnology sector, with systematic screening highlighting an ROE of 89.41% that substantially exceeds typical sector benchmarks. The company's current market capitalization of $176.1 billion positions it as a large-cap pharmaceutical enterprise trading at $324.39, representing a 17.1% decline from its 52-week high of $391.29. The TTM P/E ratio of 22.45 reflects a moderate valuation relative to the biotechnology sector, while the trailing twelve-month earnings per share of $14.38 establishes a tangible profitability foundation.

The fundamental screening model flags several operational strengths:

• Revenue growth of 9.07% year-over-year indicates sustained market expansion, while EPS growth of 31.27% demonstrates accelerating bottom-line performance that outpaces top-line expansion
• Operating margin of 28.8% and net margin of 20.96% reflect substantial pricing power and operational efficiency within a competitive pharmaceutical landscape
• Beta of 0.43 signals lower volatility characteristics relative to broader equity markets, potentially appealing to risk-adjusted screening criteria

The capital structure presents material considerations for fundamental analysis. The debt-to-equity ratio of 6.31 indicates aggressive financial leverage, substantially above pharmaceutical sector norms. The current ratio of 1.14 provides modest short-term liquidity coverage. The P/B ratio of 20.36 suggests the market assigns significant premium to intangible assets, likely reflecting patent portfolios and pipeline valuations beyond tangible book value of $16.07 per share.

From a research perspective, Amgen's profitability profile distinguishes it within the biotechnology universe, though the elevated leverage warrants ongoing balance sheet monitoring as interest rate environments evolve.